US spin-out of German MPI for molecular genetics, Harbinger Health Inc, has started a collaboration with Memorial Sloan Kettering Cancer Centre to turboboost recruiting for its Core-HH study. The study aims to validate a blood test that predicts tumour developement in cancer stage I.
ADVERTISEMENT